COMPOSITION FOR SKIN WHITENING OR WOUND TREATMENT, CONTAINING LIQUID PLASMA

Abstract

The present invention relates to a composition for skin whitening or wound treatment including liquid-type plasma, and more particularly, to a cosmetic composition for skin whitening and a pharmaceutical composition for treating and preventing skin pigmentation diseases which contain liquid-type plasma as an active ingredient. In addition, the present invention relates to a pharmaceutical composition for wound treatment, a quasi-drug composition, and a health functional food composition, which include liquid-type plasma and a growth factor as active ingredients, and a wound treatment method including a step of administering the composition to a subject or a step of applying the composition on the skin. The composition including liquid-type plasma and a growth factor of the present invention is capable of inducing the proliferation of fibroblasts, thereby exhibiting excellent wound treatment efficacy. Accordingly, the composition including liquid-type plasma and a growth factor of the present invention can be usefully applied to medicines including external preparations for wound treatment, etc.

Claims

1. A method of preparing liquid-type plasma, the method comprising: (a) a step of filling a plasma generator with a carrier gas; (b) a step of supplying a voltage of 0.5 kV to 20 kV and a frequency of 10 to 30 kHz to the plasma generator to generate plasma; and (c) a step of irradiating a liquid material with the generated plasma.

2. The method according to claim 1, wherein the carrier gas of step (a) is one or more selected from the group consisting of nitrogen, helium, argon, and oxygen.

3. The method according to claim 1, wherein the liquid material of step (c) is water, saline, a buffer, or a culture medium.

4. A liquid-type plasma composition, comprising the liquid-type plasma prepared by the method according to claim 1.

5. A liquid-type plasma composition, comprising the liquid-type plasma prepared by the method according to claim 2.

6. A liquid-type plasma composition, comprising the liquid-type plasma prepared by the method according to claim 3.

7. A method of preventing or treating skin pigmentation diseases, the method comprising a step of administering the pharmaceutical composition including the liquid type plasma composition according to claim 4 as an active ingredient to a subject.

8. The method according to claim 7, wherein the skin pigmentation diseases are one or more selected from the group consisting of melasma, freckles, a lentigo, a nevus, drug-induced pigmentation, post-inflammatory pigmentation, and hyperpigmentation caused by dermatitis.

9. (canceled)

10. A cosmetic composition for skin whitening, comprising the liquid-type plasma composition according to claim 4 as an active ingredient.

11. A method of treating a wound, the method comprising a step of administering the pharmaceutical composition including the liquid type plasma composition according to claim 4 as an active ingredient to a subject.

12. The method according to claim 11, wherein the pharmaceutical composition further comprises a growth factor.

13. The method according to claim 12, wherein the growth factor is an epidermal growth factor (EGF), platelet-derived growth factor-AA (PDGF-AA), insulin-like growth factor-1 (IGF-1), transforming growth factor- (TGF-), or a fibroblast growth factor (FGF).

14. The method according to claim 11, wherein the wound is a puncture wound, decortication, a rash, inflammation, an ulcer, or a skin injury due to scratches.

15-20. (canceled)

Description

DESCRIPTION OF DRAWINGS

[0045] FIGS. 1A and 1B illustrate a method of preparing liquid-type plasma (nonthermal plasma treated solution, NTS) according to the present invention.

[0046] FIG. 2 illustrates a pigmentation inhibition effect of liquid-type plasma according to the present invention in Zebrafish.

[0047] FIG. 3 illustrates a pigmentation inhibition effect of liquid-type plasma according to the present invention in human skin tissue.

[0048] FIGS. 4A and 4B illustrate a tyrosinase activity inhibition effect of liquid-type plasma according to the present invention in human skin tissue.

[0049] FIG. 5 illustrates toxicity test results of liquid-type plasma according to the present invention in melanocytes.

[0050] FIGS. 6A and 6B illustrate a melanogenesis marker reduction effect of liquid-type plasma according to the present invention in human melanocytes.

[0051] FIG. 7 illustrates a wound treatment effect of liquid-type plasma according to the present invention.

[0052] FIG. 8 illustrates cytotoxicity test results of liquid-type plasma according to the present invention.

BEST MODE FOR CARRYING OUT THE INVENTION

[0053] Human foreskin tissue was cultured in Transwell (DMEM high glucose+4% FBS), and then treated with liquid-type plasma at a rate of 1 min/1 ml. After 3 days of culturing, the tissue was fixed and a pigmentation degree thereof was observed through Fontana-Masson staining. As a result, it was confirmed that epidermal staining in the human skin tissue treated with the liquid-type plasma was weaker than that in a control.

MODE FOR CARRYING OUT THE INVENTION

[0054] Hereinafter, the present invention will be described in more detail with reference to the following Examples. It will be apparent to those skilled in the art that the Examples are merely for concretely explaining the invention and therefore, there is no intent to limit the invention to the Examples.

Example 1. Preparation of Liquid-Type Plasma

Example 1-1. Preparation of Liquid-Type Plasma (Nonthermal Plasma-Treated Solution, NTS)

[0055] 10 ml of F12 (10% FBS 24 ug/ml 3-isobutyl-1-methylxanthine, 80 nM 12-O-tetradecanoyl Phorbor 13-acetate (TPA), 1.2 g/ml bFGF, 0.1 ug/ml cholera toxin) was placed in a container to prepare a culture medium. The culture medium was treated with plasma at an intensity of 4 KV under a condition of 1 minute per ml at a distance 1 cm spaced apart from the culture medium using helium and oxygen as carrier gases, thus preparing liquid-type plasma (plasma-treated culture medium). A method of preparing the liquid-type plasma is illustrated in FIG. 1A.

Example 1-2. Preparation of Composition Including Liquid-Type Plasma (NTS) and Growth Factor

[0056] To investigate an effect of the liquid-type plasma according to the present invention and a growth factor on wound treatment, cell migration in fibroblasts was evaluated using DMEM High Glucose+10% FBS, as a culture medium, and EGF, as a growth factor. First, power having a voltage of 15 kV and a frequency 15 kHz was supplied. The culture medium was treated with plasma by means of a plasma generator using nitrogen gas as a carrier gas, thus preparing liquid-type plasma (plasma-treated culture medium). A method of preparing the liquid-type plasma is illustrated in FIG. 1B.

Example 2. Investigation of Effect of Liquid-Type Plasma on Skin Whitening

Example 2-1. Pigmentation Inhibition Effect in Zebrafish

[0057] Embryos collected from zebrafish were placed in a zebrafish embryo culture medium (egg water, 0.2 g sea salt/L) and were allowed to develop for 24 hours, followed by being treated with the liquid-type plasma prepared according to Example 1. To increase the penetration of the sample into chorions during sample processing, chorions of the embryos were pierced with tweezers. 24 hours after the sample treatment, embryos showing toxicity were removed. Chorions of the remaining embryos were completely removed, and then the chorion-removed embryos were treated at the same concentration. 48 hours after the treatment, the degrees of pigmentation in the treated samples, compared to a control, were observed with a stereomicroscope. Results are shown in FIG. 2.

[0058] Referring to FIG. 2, it was confirmed that, in the case of the zebrafish treated with the liquid-type plasma, pigmentation is inhibited compared to a control.

Example 2-2. Pigmentation Inhibition Effect in Human Skin Tissue

[0059] Human foreskin tissue was cultured in Transwell (DMEM high glucose+4% FBS), and then was treated with the liquid-type plasma prepared according to Example 1 at a rate of 1 min/1 ml. After incubation for 3 days, the human foreskin tissue was fixed and a pigmentation degree thereof was observed through Fontana-Masson staining. Results are shown in FIG. 3.

[0060] Referring to FIG. 3, it was confirmed that epidermal staining in the human skin tissue treated with the liquid-type plasma was weaker than that in a control.

Example 2-3. Tyrosinase Activity Inhibition Effect in Human Skin Tissue

[0061] 210.sup.6 of a human foreskin sample was seeded in a 60 mm dish, and then treated with the liquid-type plasma prepared according to Example 1 at a rate of 1 min/1 ml. After incubation for 24 hours and fixation, Western blotting and PCR analysis were performed and tyrosinase activity and melanin content were measured. Results are shown in FIGS. 4A and 4B.

[0062] As shown in FIG. 4, it was confirmed that tyrosinase, MITF, and melanin content were significantly reduced in the human skin tissue treated with the liquid-type plasma.

Example 2-4. Toxicity Evaluation in Melanocytes

[0063] Human melanocytes were treated with the liquid-type plasma prepared according to Example 1, and then cytotoxicity thereof was observed over time. Results are shown in FIG. 5.

[0064] As shown in FIG. 5, it was confirmed that the liquid-type plasma according to the present invention did not exhibit toxicity in the human melanocyte.

Example 2-5. Melanogenesis Marker Reduction Effect in Human Melanocytes

[0065] Human melanocytes were treated with the liquid-type plasma prepared according to Example 1, and reduction of melanogenesis markers in the human melanocytes was observed over time. Results are shown in FIGS. 6A and 6B.

[0066] As shown in FIG. 6, it was confirmed that the liquid-type plasma according to the present invention had a reduction effect on melanogenesis markers in the human melanocyte. Here, an RNA level of tyrosinase as well as protein levels of the melanogenesis markers were reduced.

Example 3. Evaluation of Wound Treatment Effect of Liquid-Type Plasma

Example 3-1. Wound Treatment Effect Evaluation

[0067] The liquid-type plasma prepared according to Example 1 was pretreated with each of 10 ng/ml and 30 ng/ml of EGF, and a human-derived fibroblast line (110.sup.5 cells) were seeded therein. After 1 hour, migration of the cells was evaluated by wound healing assay.

[0068] Meanwhile, as comparative examples, fibroblasts were seeded in each of liquid-type plasma and EGF, and then migration of the fibroblasts therein was observed. Results are shown in FIG. 7.

[0069] Referring FIG. 7, in the comparative examples, a wound treatment effect was not exhibited in the group treated with only the liquid-type plasma, but was exhibited in the group treated with only EGF. In the group treated with both the liquid-type plasma and EGF, the wound treatment effect was significant, compared to the group treated with only EGF.

Example 3-2. Cytotoxicity Investigation

[0070] To investigate whether the composition containing including the liquid-type plasma according to the present invention and EGF exhibited cytotoxicity against fibroblasts, the viability of the fibroblasts was evaluated by MTT. Results are shown in FIG. 8.

[0071] Referring to FIG. 8, it was confirmed that the composition according to the present invention did not exhibit cytotoxicity against fibroblasts.

[0072] While this invention has been particularly shown and described with reference to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims. The preferred embodiments should be considered in descriptive sense only and not for purposes of limitation. Therefore, the scope of the invention is defined not by the detailed description of the invention but by the appended claims, and all differences within the scope of equivalents will be construed as being included in the present invention.

INDUSTRIAL APPLICABILITY

[0073] A composition containing liquid-type plasma as an active ingredient according to the present invention exhibits an excellent skin whitening effect and an excellent treatment or prevention effect on skin pigmentation diseases.

[0074] In addition, a composition including the liquid-type plasma and a growth factor of the present invention can induce the proliferation of fibroblasts, thereby exhibiting excellent wound treatment efficacy. Accordingly, the composition according to the present invention can be usefully applied to external preparations for wound treatment, medicines, and the like.